What is the PKA SoftTouch Path to Profit?

We are now raising a second round of capital to complete clinical trials and secure licenses with pharmaceutical companies who will then manufacture and sell our device.  By investing, you will receive shares and become a co-owner of PKA SoftTouch, having the potential to profit from the sale of each and every device.

PKA SoftTouch Corp. follows a Licensing Model for revenue generation. Revenue streams could be derived from two sources, royalties and a manufacturing profit.


  • An initial $1,373,338 by 47 investors, who have full confidence in the company and device
  • Followed by another $202,226 by 141 investors in Round I of our Frontfundr campaign
  • We are ready to start veterinary clinical trials. As of 21 July 2020, we had already met with our Pharmaceutical Regulatory Consultants, McCarthy Consultant Services, and were three weeks away from finalizing moulds; steps that position us to approach companion animal medication manufacturers with confidence and the data required.
  • We are now inviting existing, new and interested investors to purchase shares.



A key component for financial success and stability is the protection of our technology. We have protected our intellectual property in 23 countries: Canada, United States, India, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, Japan, New Zealand, South Africa and Australia. Patents are still pending in Brazil and Argentina.

For further details on this investment offering and how to invest, please click below.


If you have additional questions, please contacts us.